Drug
Revefenacin clinical trials
Also written TD-4208 and Yupelri.
- studies test it
- 21
- open now
- 2
- in phase 3
- 6
- first study started
- 2007
Keep track of what changes. Save the revefenacin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2015 (6)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
- Phase 3
- 6
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 4
Mylan Inc. (13) · University of Tennessee Graduate School of Medicine (3) · Mylan Pharma UK Ltd. (2) · University of California, Los Angeles (1) · Theravance Biopharma (1) · GlaxoSmithKline (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses revefenacin is read from its arms, and is right about nine times in ten.
Testing it · 21
- Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)Not yet recruitingPhase 4University of Tennessee Graduate School of MedicineNCT07721922Written as Revefenacin
- Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting BronchodilatorsRecruitingPhase 4University of Tennessee Graduate School of MedicineNCT07133880Written as Revefenacin 175 µg, Formoterol 20 µg
- Revefenacin in Acute Respiratory Insufficiency in COPDCompletedPhase 2University of California, Los AngelesNCT04315558Written as Revefenacin Inhalation Solution [Yupelri]
- Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPDCompletedPhase 4University of Tennessee Graduate School of MedicineNCT04655170Written as Revefenacin (YUPELRI) & Formoterol (Perforomist)
- Phase 4 COPD and Suboptimal Inspiratory Flow RateCompletedPhase 4Theravance BiopharmaNCT05165485Written as Revefenacin
- Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)CompletedPhase 3Mylan Pharma UK Ltd.NCT05046795Written as Revefenacin 175 mcg in 3 ML Inhalation Solution
- Fasting Bioavailability Study of Mylan's Revefenacin Inhalation SolutionCompletedPhase 1Mylan Pharma UK Ltd.NCT05207111Written as Revefenacin Inhalation Solution
- Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic ImpairmentCompletedPhase 1Mylan Inc.NCT02581592Written as TD-4208
- Pharmacokinetics of TD-4208 in Patients With Severe Renal ImpairmentCompletedPhase 1Mylan Inc.NCT02578082Written as TD-4208
- Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Mylan Inc.NCT02459080Written as TD-4208
- A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Mylan Inc.NCT02040792Written as TD-4208
- 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Mylan Inc.NCT01704404Written as TD-4208
- A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Mylan Inc.NCT02109172Written as TD-4208
- A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Mylan Inc.NCT02518139Written as TD-4208
- Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3Mylan Inc.NCT02512510Written as TD-4208
- A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPDCompletedPhase 3Mylan Inc.NCT03573817Written as Revefenacin
- Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2Mylan Inc.NCT03064113Written as TD-4208 700 μg
- TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male SubjectsCompletedPhase 1Mylan Inc.NCT02772159Written as TD-4208
- Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPDCompletedPhase 3Mylan Inc.NCT03095456Written as Revefenacin
- Thorough QT (TQT) Study of TD-4208 in Healthy SubjectsCompletedPhase 1Mylan Inc.NCT02820311Written as TD-4208 175 mcg
Codes
What other systems call revefenacin · ClinicalTrials.gg INT006351
- MeSH (NLM) C583570revefenacinOne source NLM
- UNII (FDA) G2AE2VE07OREVEFENACINConfirmed FDA, NLM, Wikidata
- RxNorm 2102775One source FDA
- Wikidata Q27278649revefenacinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152200RevefenacinOne source FDA
- DrugBank DB11855One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C583570 | revefenacin | One source NLM |
| UNII (FDA) | G2AE2VE07O | REVEFENACIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2102775 | — | One source FDA |
| Wikidata | Q27278649 | revefenacin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152200 | Revefenacin | One source FDA |
| DrugBank | DB11855 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.